RAASi as a fundamental pillar in HF
Video navigation menu
- Recommended therapies for HFrEF 0:23
- Real world evidence of registry studies 2:05
- The dilemma of hyperkalemia vs. RAASI benefits 3:15
- Management with RAASI in those at risk for hyperkalemia 4:51
This lecture by Andrew Coats was part of an accredited symposium "Potassium binding in heart failure management - Enabling guideline-recommended RAASi therapy" held during the virtual ESC Congress 2021.
Andrew Coats, MD is Academic Vice-President at University of Warwick, Coventry, UK and Monash University, Melbourne, Australia. He is also president of the Heart Failure Association of the ESC.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Vifor Pharma.